Health-related life quality as assessed by the Short-Form-36 Health Survey (SF-36) at baseline and after therapy
| Placebo | Bosentan | p-value | |||
| Baseline | 12 weeks | Baseline | 12 weeks | ||
| Subjects n | 10 | 9 | 20 | 14 | |
| Physical functioning | 43.3±28.1 | 55.6±20.1 | 27.5±15.3 | 23.2±19.9 | 0.067 |
| Role limitations due to physical health | 23.0±38.1 | 53.1±47.1 | 16.3±33.7 | 7.1±26.7 | 0.082 |
| Body pain | 70.8±32.6 | 80.8±29.2 | 78.3±28.0 | 70.2±31.7 | 0.413 |
| General health perceptions | 50.5±20.0 | 62.4±19.0 | 43.2±20.9 | 39.1±20.4 | 0.018 |
| Vitality | 47.8±20.0 | 50.0±25.2 | 36.4±19.3 | 34.6±18.5 | 0.571 |
| Social functioning | 70.0±36.4 | 89.1±15.6 | 58.1±32.0 | 57.1±28.5 | 0.230 |
| Role limitations due to emotional problems | 63.3±45.7 | 79.2±35.4 | 43.3±49.7 | 59.5±49.2 | 0.970 |
| Mental health | 76.0±19.2 | 87.1±13.5 | 66.6±15.0 | 64.9±17.0 | 0.023 |
| Total physical health | 47.4±23.2 | 61.1±21.5 | 38.5±14.8 | 34.9±18.3 | 0.032 |
| Total mental health | 61.6±23.4 | 68.9±21.4 | 50.6±20.7 | 51.1±20.8 | 0.263 |
| Total SF-36 Score | 56.2±21.3 | 66.9±19.6 | 46.1±17.6 | 44.5±18.7 | 0.039 |
Data are presented as mean±sd, unless otherwise stated.